MedPath

Effect of physical activity on functional capacities on older adults with sarcopenic obesity

Phase 1
Completed
Conditions
Musculoskeletal Diseases
Registration Number
PACTR202306912191110
Lead Sponsor
FERHI
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
72
Inclusion Criteria

BMI > 30 Kg/m²,
- A Handgrip force (HF) <17 N,
- Gait speed <1.0 m/s50,
- Be over 65 years of age,
- Able to verbally communicate with the experimenters, and physically independent

Exclusion Criteria

- The presence of neurological or cognitive impairments,
- Severe cardiovascular problems,
- Severe musculoskeletal deformities or injuries of the lower limb,
- Comorbidities or chronic diseases,
- Medication use that could interfere with testing,
- A Montreal Cognitive Assessment (MoCA) test score of <26

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Trained group exhibited an increase in comfortable walking speed (+80%, p<0.001) and step length (+38%, p<0.05)
Secondary Outcome Measures
NameTimeMethod
After the PSM program, TG showed a significant increase in LBM (+10%, p<0.05) and a decrease in FBM (-12.4%, p<0.05) and demonstrated improved physical performance in the various exercises of the senior fitness test (p<0.005). . Additionally, the durations of the initial left and right double stance phases (-4.1%, -4%, respectively) and the left and right pre-swing phases (-3%, -3%, respectively; p<0.05) decreased. Moreover, TG demonstrated a reduction in CoP velocity (-26%, p<0.01). Notably, TG also displayed increased GRFv (+16%, p<0.05). These gait modifications were associated with a decreased muscle activity in SOL during the first stance phase (-17.5%; p<0.05) and pre-swing phase (-15.1%; p<0.05). Additionally, TA activity decreased during the first double stance phase (-18.6%; p<0.05) and single stance phase (-26.6%; p<0.01), while GM activity decreased during the pre-swing phase (-23.9%; p<0.01).
© Copyright 2025. All Rights Reserved by MedPath